Radiation Therapy in the Oncology Market Size, Share & Trends Analysis Report By Radiation Type (External Beam Radiation, Internal Beam Radiation), By Product Type (Oncology Systems, Proton Solutions, Others), By Therapy (Stereotactic Radiosurgery (SRS), Image-Guided Radiation Therapy (IGRT), Intensity-Modulated Radiation Therapy (IMRT), Volumetric-Modulated Arc Therapy (VMAT), Brachytherapy), By End-User (Hospitals and Medical Research Institutes, Specialized Radiotherapy Centers) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Radiation Therapy in the Oncology Market Size

The global radiation therapy in the oncology market size was valued at USD 10944.75 million in 2025 and is projected to grow from USD 13340.56 million in 2026 to USD 65000.78 million by 2034, registering a CAGR of 21.89% during the forecast period from 2026 to 2034. North America dominated the radiation therapy in the oncology market with a market share of 38.4% in 2025.

Radiation therapy in oncology is a treatment method to treat any cancer/tumor with the help of radiation. Radiation therapy uses beams of photons, protons, heavy ions, and other particles. These radiation beams of intense energy are used to destroy or shrink cancer/tumor cells. Roentgen discovered the X-ray in 1895, and since then, ionizing radiation has been applied for cancer treatment. The controlled ionizing radiation dose damages the DNA of the cancer cell when compared with the effect on normal tissues, thus providing radiation treatment benefits for cancer patients.

The term' radiation therapy' primarily refers to external and internal beam radiation therapy. External beam radiation therapy is done with the help of a machine outside the patient's body that produces a high-energy radiation beam and then aims the beam at a localized, precise point or area of therapy on the patient's body. However, internal beam radiation therapy places radiation (radioactive source) inside the patient's body. The radiation therapy systems (machines) present in the market are linear accelerators (LINAC), cyclotrons, synchrotrons, synchrocyclotrons, and conventional and electronic brachytherapy systems.

Top 4 Key Highlights

• Oncology systems dominate the product type segment
• Stereotactic radiosurgery (SRS) dominates the therapy segment
• Hospitals and medical research institutes dominate the end-user segment
• North America is the highest shareholder in the global market

Radiation Type Insights

The external beam radiation segment accounts for the largest market share and is anticipated to exhibit a CAGR of 4.6% over the forecast period. External beam radiation is where the radiation beam or beams of x-ray, photon, proton, electron, or heavy ion is generated outside the patient's body by a particle accelerator. These radiation beams are delivered to the patient's cancer/tumor to either shrink or destroy it. In addition, the adoption of modern external beam radiation systems is rapidly increasing due to the significant change in the radiation beam type. This allows clinicians to reduce the radiation exposure to healthy tissues surrounding the target area and automate the radiation therapy to improve the efficacy and precise and accurate radiation dose delivery.

Request Customizationto receive a tailored report.

Product Type Insights

The oncology system segment dominates the global market and is expected to grow at a CAGR of 4.4% over the forecast period. Radiation therapy systems in the oncology segment include conventional radiation systems and brachytherapy systems, which are most used in the market. These systems allow clinicians to perform cancer treatments through external or internal beam radiation. The most common radiation beam is a superficial X-ray or photon for teletherapy. The brachytherapy consists of various radioactive sources depending on the type of cancer/tumor and its location.

Therapy Insights

The stereotactic radiosurgery (SRS) segment owns the highest market share and is predicted to exhibit a CAGR of 5.2% over the forecast period. Stereotactic radiosurgery (SRS) is not surgery as it does not include any incision or general anesthesia. SRS was created by neurosurgeons and physicists about five decades ago to deliver radiation to localized targets in the brain. The SRS destroys the DNA of the tumor cells in the same manner as another form of radiation, resulting in the tumor cells dying because of the inability to grow. In addition, the SRS uses 3D computerized imaging and a frame placed on the patient's head to direct the radiation beam to a precise target and deliver a high radiation dose in a single session.

End-User Insights

The hospitals and medical research institutes segment is the most significant contributor to the market and is estimated to exhibit a CAGR of 4.8% over the forecast period. The end-user of the hospitals and medical research institutes segment is the primary buyer of radiation therapy systems, owing to the increasing geriatric population, rising incidence and prevalence of cancer/ tumor, and continuous technological advancements in radiation therapy systems.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global radiation therapy in the oncology market shareholder and is estimated to exhibit a CAGR of 4.6% during the forecast period. The North American medical device market is the early adopter of advanced technology. Companies in this region mainly offer their products and solutions, as many other countries accept U.S. FDA regulatory approval. The North American market provides growth opportunities to the companies, owing to the increased adoption of technologies such as advanced proton and heavy-ion radiation therapy systems for the healthcare industry. In addition, the rising incidence of cancer patients and the presence of several companies in this region contribute to the market's growth. North American market players such as Accuray Inc., Mevion Medical Systems Inc., TeamBest Group, Reflexion Medical Inc., Sensus Healthcare Inc., Xoft Inc. (iCAD Inc.), and Zap Surgical Systems Inc., among others, and other international players have been making significant developments in the region, thus leading the market forward.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe Radiation Therapy in the Oncology Market Trends

Europe is anticipated to exhibit a CAGR of 5.3% over the forecast period. Europe's radiation therapy in the oncology market is the second most lucrative market globally and has good growth potential. The significant factor contributing to the market's growth is the availability of government reimbursement plans for European citizens. Further, the existence of cross-border alliances in Europe suggests that a person who is a citizen of a nation that is a member of the European Union (EU) is qualified to seek medical attention in any country within the EU region. In addition, Europe has advanced health technology assessment plans, measuring the value added by new technology to the healthcare sector, offering market growth potential. This region includes Germany, France, Italy, the U.K., Spain, and Rest-of-Europe. Among these countries, Germany currently acquires a significant market share, followed by France and the U.K.

The market inthe Asia-Pacific region has been the fastest-growing region in terms of technological innovations and developments. The increasing prevalence of cancer/tumors, rising per capita income, and elevating geriatric population are the prime factors propelling the growth of radiation therapy in the oncology market in these regions. China acquired the dominant market share, followed by Japan in Asia-Pacific. In addition, China is one of the nations with massive potential for profitable expansion by key global radiation therapy market players. A large population base with improving healthcare infrastructure makes China region a profit-making market. Furthermore, Japan has received many regulatory approvals regarding the radiation therapy market, along with the supportive nature of the Japanese government in implementing advanced technologies in the healthcare sector. This leads the companies to invest in Japan and thus promotes the growth of the market.

Rest-of-the-World (RoW) market includes economies such as the Kingdom of Saudi Arabia (KSA), Israel, Qatar, Egypt, Kuwait, and Lebanon. The economies in the Middle East region have always been working toward technological developments and scientific innovations. The market for radiation therapy is proliferating, owing to the rising adoption of technological advancement in the healthcare industry supported by government initiatives. The rising prevalence and incidence of cancer, coupled with the increasing geriatric population, are also propelling the growth of global market around the Rest-of-the-World (RoW).

List of Key and Emerging Players in Radiation Therapy in the Oncology Market